Bristol-myers Squibb Compnay

Balaji Seshadri

Pravin Sudhakar Shirude

Robert Michael Borzilleri

James A Johnson

Brian E Fink

Joanne M Smallheer

Upender Velaparthi

Charles G Clark

Jayakumar Sankara Warrier

Zulan Pi

Nicholas Ronald Wurtz

Ellen K Kick

Amit Kumar Chattopadhyay

Vishweshwaraiah Baligar

Hasibur Rahaman

Lalgudi S Harikrishnan

Peiying Liu

Chetan Padmakar Darne

Meriah Neissel Valente

Gopikishan Tonukunuru

Raju Mannoori

Manjunatha Narayana Rao Kamble

The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

Phenylpyrrolidinone formyl peptide 2 receptor agonists

The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases. 

The invention relates generally to compounds of formula (I) that modulate the activity of TGF&#x3b2;R-1 and TGF&#x3b2;R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention. 

TGF beta receptor antagonists

The invention relates generally to compounds that modulate the activity of TGF&#x3b2;R-1 and TGF&#x3b2; R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

TGF&#x3b2; receptor antagonist

Growing community of inventors

Hosur, India

Balaji Seshadri